GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.
CEO: Paul V. Goode. Company website
GlucoTrack, Inc. (GCTK) trades at $2.50, down 1.96% on the day, as of Sep 20, 2026 15:00 UTC.
GlucoTrack, Inc. has a market capitalisation of $1.42M, calculated from the live GCTK share price and shares outstanding.
GCTK has no meaningful price-to-earnings ratio: GlucoTrack, Inc. lost $49.16 per share over the last twelve months, and a P/E is only defined on positive earnings.
GlucoTrack, Inc. generated revenue of $0.00 over the trailing twelve months.
GCTK has traded between $0.29 and $13.50 over the past 52 weeks, and the last price is 81.5% below that high.
Yes. GlucoTrack, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.
GlucoTrack, Inc. is classified under the Healthcare sector and the Medical - Instruments & Supplies industry, and is domiciled in IL .
Paul V. Goode is the chief executive of GlucoTrack, Inc., which employs 11 people.
QFI Terminal shows GCTK with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open GCTK in Terminal See plans